JP2003528610A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003528610A5 JP2003528610A5 JP2001570750A JP2001570750A JP2003528610A5 JP 2003528610 A5 JP2003528610 A5 JP 2003528610A5 JP 2001570750 A JP2001570750 A JP 2001570750A JP 2001570750 A JP2001570750 A JP 2001570750A JP 2003528610 A5 JP2003528610 A5 JP 2003528610A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- laminin
- angiogenic activity
- isolated
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 230000001772 anti-angiogenic effect Effects 0.000 description 15
- 108010085895 Laminin Proteins 0.000 description 9
- 239000003814 drug Substances 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000012634 fragment Substances 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000144080 Alestes Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000003732 Cat-scratch disease Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000013058 Weber syndrome Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000007293 brain stem infarction Diseases 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 108010042502 laminin A Proteins 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N trimethylxanthine Natural products CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19287500P | 2000-03-29 | 2000-03-29 | |
| US60/192,875 | 2000-03-29 | ||
| PCT/US2001/009921 WO2001073033A2 (en) | 2000-03-29 | 2001-03-28 | Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528610A JP2003528610A (ja) | 2003-09-30 |
| JP2003528610A5 true JP2003528610A5 (enExample) | 2008-05-22 |
Family
ID=22711380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001570750A Pending JP2003528610A (ja) | 2000-03-29 | 2001-03-28 | マチンおよび他のラミニンドメインの抗血管形成特性および抗腫瘍特性 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20030108540A1 (enExample) |
| EP (1) | EP1268783B9 (enExample) |
| JP (1) | JP2003528610A (enExample) |
| AT (1) | ATE331785T1 (enExample) |
| AU (1) | AU4599401A (enExample) |
| CA (1) | CA2403857A1 (enExample) |
| DE (1) | DE60121146T2 (enExample) |
| NZ (1) | NZ521625A (enExample) |
| WO (1) | WO2001073033A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050220760A1 (en) * | 2004-04-02 | 2005-10-06 | Clemson University | Novel immunotherapy |
| BRPI0502497A (pt) * | 2005-06-28 | 2007-02-06 | Univ Minas Gerais | uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças |
| CA3098871A1 (en) * | 2018-05-08 | 2019-11-14 | Rutgers, The State University Of New Jersey | Aav-compatible laminin-linker polymerization proteins |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5092885A (en) * | 1987-02-12 | 1992-03-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Peptides with laminin activity |
| US5211657A (en) * | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5266328A (en) * | 1990-08-27 | 1993-11-30 | Regents Of The University Of Minnesota | Laminin a chain polypeptides from the carboxy terminal globular domain |
| EP0567578A1 (en) * | 1991-01-25 | 1993-11-03 | The Regents Of The University Of Minnesota | Laminin a chain domain vi polypeptides |
| US6013628A (en) * | 1994-02-28 | 2000-01-11 | Regents Of The University Of Minnesota | Method for treating conditions of the eye using polypeptides |
| US5696229A (en) * | 1995-03-16 | 1997-12-09 | The University Of Virginia Patent Foundation | Polypeptide with laminin cell adhesion and morphogenesis activity |
| US6080728A (en) * | 1996-07-16 | 2000-06-27 | Mixson; A. James | Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy |
| DE19701607A1 (de) * | 1997-01-17 | 1998-07-23 | Hoechst Ag | Anitkörper, die an die Nidogen-Bindungsdomäne des Laminins binden, deren Herstellung und Verwendung |
| WO2000056754A1 (en) * | 1999-03-19 | 2000-09-28 | Human Genome Sciences, Inc. | 48 human secreted proteins |
-
2001
- 2001-03-28 DE DE60121146T patent/DE60121146T2/de not_active Expired - Fee Related
- 2001-03-28 NZ NZ521625A patent/NZ521625A/en unknown
- 2001-03-28 EP EP01918982A patent/EP1268783B9/en not_active Expired - Lifetime
- 2001-03-28 JP JP2001570750A patent/JP2003528610A/ja active Pending
- 2001-03-28 CA CA002403857A patent/CA2403857A1/en not_active Abandoned
- 2001-03-28 AU AU4599401A patent/AU4599401A/xx not_active Withdrawn
- 2001-03-28 AT AT01918982T patent/ATE331785T1/de not_active IP Right Cessation
- 2001-03-28 WO PCT/US2001/009921 patent/WO2001073033A2/en not_active Ceased
-
2002
- 2002-09-30 US US10/262,670 patent/US20030108540A1/en not_active Abandoned
-
2007
- 2007-05-07 US US11/797,697 patent/US20080167227A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2315438T3 (es) | Composicion de inhibidor de metaloproteinasa de tejido quimicamente modificado de tipo tres (timp-3) y procedimientos. | |
| US6689580B1 (en) | Growth factor | |
| JPH10502349A (ja) | インテグリンα▲下４▼β▲下１▼のＶＣＡＭ−１またはフィブロネクチンへの結合を阻害する方法 | |
| US5817485A (en) | Nucleic acids and cells for recombinant production of fibroblast growth factor-10 | |
| JPH05502161A (ja) | 組換えヒト８因子誘導体 | |
| JP2001509029A (ja) | ヒトタンパク質 | |
| JP2002506643A (ja) | 乳房腫瘍組織に由来するヒト核酸配列 | |
| JPH11504938A (ja) | クニッツ型プロテアーゼ阻害因子 | |
| JPWO2010128672A1 (ja) | 遺伝子組み換えゼラチンを含む血管新生誘導剤 | |
| JPH09509324A (ja) | 増殖阻止ホメオボックス遺伝子 | |
| JPH07509229A (ja) | ウシ膵トリプシン阻害因子から誘導される因子Ｘａの阻害因子 | |
| JPH02222684A (ja) | 植物性リボソーム不活化タンパク質をコードするヌクレオチド配列 | |
| JPH05506646A (ja) | ヒト・フォンビルブラント因子のクローニング及び製造、並びにその使用方法 | |
| JP2003528610A5 (enExample) | ||
| JP2000504676A (ja) | Ｖｉｐアナログの合成 | |
| CN117157308A (zh) | 细胞穿膜肽变体及其用途 | |
| JP2003528609A5 (enExample) | ||
| US6121237A (en) | Neutrophil stimulating peptides | |
| CN110139871A (zh) | 用于治疗中风和相关凝血障碍的凝血酶抑制剂 | |
| JP2002539829A5 (enExample) | ||
| CN106916210A (zh) | 一种具有抗脑缺血作用的多肽及其应用 | |
| JP2008502323A5 (enExample) | ||
| US5807828A (en) | Platelet aggregation inhibitors | |
| JPH09512422A (ja) | カイメース阻害活性を有するα−１−抗キモトリプシン類似体 | |
| JPH11506466A (ja) | 組織因子のペプチドフラグメント、及び凝血障害の治療及び予防のためのそれらの使用 |